


Prevention of Paclitaxel-related neurotoxicity



PRINCIPAL INVESTIGATORS:
Prof. Dr. Matthias Endres, PD Dr. Wolfgang Böhmerle, PD Dr. Petra Hühnchen
Charité



SUMMARY

Neurotoxicity is a common and potentially long-lasting side effect of cytotoxic drugs including Paclitaxel (PTX). Preclinical studies have shown that neuronal damage by PTX can be reduced with a marketed drug that can readily be repositioned. With their previous 2018 SPARK-BIH validation fund, the team successfully developed a roadmap for clinical translation of this key-finding. Currently, it plans to conduct an explorative proof-of-concept phase II clinical trial to prove that co-administration of the repositioned drug prevents neurological side effects of PTX. During this funding period, the team is going to initiate the trial and perform a preliminary interim safety analysis to demonstrate safety and feasibility of the intervention.

PROJECT GOALS

- Obtain ethical approval by BfArM & LaGeSo
- Set-up clinical trial including e-documentation, infrastructure & medication kits
- Complete interim safety study with 20 breast cancer patients

LONG-TERM GOALS

- Complete clinical phases with further funding
- Change medical practice

PREVIOUS SPARK FUNDING

- Track 1 2018